Brain+ begins early activity and brand building in the US
Brain+ begins early activity and brand building in the US The United States (US) is a key future market for Brain+, and early brand building and exploration is now ongoing Brain+ has been selected and featured as a 2022 TMC-Denmark BioBridge Partner in the new Texas Medical Center (TMC) 2022 Biobridge e-book. TMC is the […]
First milestone met
Brain+ meets milestone with Rox Health (Roche Germany) Rox Health has approved the German version of Brain+’s first digital dementia product, CST-Therapist Companion, for commercial launch. Meeting this milestone unlocks access for Brain+ to additional expert resources in the Rox Health/Roche organization and triggers a minor milestone payment. The following milestones will be product launch […]
New Research report values Brain+
New research report values Brain+ at DKK 4.1 per share in the base case, and DKK 6.4 in the bull case. The research report concludes that “Brain+ is in a strong position to grow towards a market leadership position within Digital Therapeutics for dementia, based on a unique and differentiated product offering… …combined with a […]
Accelerated launch Q2 2023
Brain+ partners with German medical distributor Advances launch of its first CST dementia product in Germany to Q2 2023 Through Coopmed, Brain+ will be represented by experienced and local medical sales managers in Germany and begin to build the customer pipeline in preparation for the commercial launch of its first CST dementia product, […]
Brain+’ new product for dementia launching Q4 2022
Brain+’ new product for dementia launching Q4 2022 Digital “CST–Therapist Companion” is launching one year ahead of plan The Brain+ “CST-Therapist Companion” is a new digital product to deliver Cognitive Stimulation Therapy (CST), a globally recognized evidence-based non-pharmaceutical dementia therapy The Danish market for the Brain+ digital CST products, of which CST-Therapist […]
Growing interest in DTx from big pharma
Brain+ is experiencing growing interest from big pharma in its Digital Therapeutics solutions for dementia. Brain+ is a first mover in the field of Digital Therapeutics (DTx) solutions to treat Alzheimer’s Disease (AD) and other types of dementia and help relieve the growing burden of these conditions on patients, relatives, and societies. According to the […]
Common Nordic digital health evaluation framework launched
Common Nordic digital health evaluation framework launched Digital Therapeutics (DTx) is a growing trend and is increasingly a recognized market providing an important supplement to the established trillion USD pharmaceutical market (traditional medicine). The DTx trend is evolving fast. In June 2022 the Nordic Digital Health and Evaluation Criteria (NordDEC) program has been created. The […]
Germany opens the DiPA reimbursement pathway
Germany opens the DiPA reimbursement pathway to support the adoption of digital health applications, underpinning the value of the #1 target market for Brain+’ first commercial dementia product, CST A significant event for Brain+ as DiPA can provide reimbursement coverage for the first Cognitive Stimulation Therapy (CST) product, expected to be launched in Germany in […]
1m SEK FORTE grant project to map digital interventions for dementia
1m SEK FORTE grant project to map digital interventions for dementia Helping Brain+ strengthen patient and care giver compliance for product development PURPOSE: The FORTE project will perform a scoping review of digital interventions for dementia and mild cognitive impairment and engage with live user panels to map state of the art in the field. […]
2021 Brain+ Annual Report
From the CEO: I am pleased with the Brain+ 2021 annual results we have presented today. With our commitment to develop medical software to detect and treat the cognitive symptoms of dementia, 2021 brought real progress. A few highlights: – Secured first strategic partnership with large pharma company in the main target market, Germany. – […]
